Spinal cord and brain MRI should be routinely performed during follow-up in patients with NMOSD

Abstract

Get full access to this article

View all access options for this article.

References

Thompson

Banwell

Barkhof

, et al. Diagnosis of multiple sclerosis: 2017 Revisions of the McDonald criteria. Lancet Neurol 2018; 17(2): 162–173.

Jurynczyk

Geraldes

Probert

, et al. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain 2017; 140(3): 617–627.

Sormani

Bruzzi

MRI lesions as a surrogate for relapses in multiple sclerosis: A meta-analysis of randomised trials. Lancet Neurol 2013; 12(7): 669–676.

Scarpazza

Signori

Prosperini

, et al. Early diagnosis of progressive multifocal leucoencephalopathy: Longitudinal lesion evolution. J Neurol Neurosurg Psychiatry 2019; 90(3): 261–267.

Wingerchuk

Lennon

Lucchinetti

, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6(9): 805–815.

Palace

Leite

, et al. A practical guide to the treatment of neuromyelitis optica. Pract Neurol 2012; 12(4): 209–214.

Weinshenker

Wingerchuk

DM.

Neuromyelitis spectrum disorders. Mayo Clin Proc 2017; 92(4): 663–679.

Kim

Paul

Lana-Peixoto

, et al. MRI characteristics of neuromyelitis optica spectrum disorder: An international update. Neurology 2015; 84(11): 1165–1173.

Kleiter

Hellwig

Berthele

, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012; 69: 239–245.

10.

Whittam

Tallantyre

Jolles

, et al. Rituximab in neurological disease: Principles, evidence and practice. Pract Neurol 2019; 19(1): 5–20.

Spinal cord and brain MRI should be routinely performed during follow-up in patients with NMOSD – No

Abstract

Get full access to this article

References